Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT03541863
- Lead Sponsor
- Fudan University
- Brief Summary
What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.
- Detailed Description
There is no evidence of treatment after progression of Ful. We retrospectively evaluated HR+, HER2- MBC patients failed on Ful 500mg as first line or second line therapy from 2014 to 2017 in 6 institutions. Treatment pattern, PFS, OS and safety were analyzed to figure out the situation and efficacy of treatment after Fulvestrant.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 131
Inclusion Criteria
- Patients who were treated with Fulvestrant between June 2014 to June 2017 as first line or second line therapy
- Patients received subsequent treatment after progressing on Fulvestrant for at least one cycle (>1 month)
- Complete medical history was available
Exclusion Criteria
- Subsequent treatment was not standard therapy (cannot be classified into endocrine therapy/ chemotherapy)
- Medical history was incomplete
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS 6 weeks Progression free survival
- Secondary Outcome Measures
Name Time Method OS From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months Overall survival
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 6 weeks
Trial Locations
- Locations (1)
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China